Do you remember DBV Technology, the biotech nugget? The latest advances, key figures for 2023, future financial plans: we take stock with you!ย
DBV Technology in Brief
DBV Technology is a biotechnology company specializing in the development of treatments for food allergies. Founded in 2002, it has made a name for itself thanks to its innovative technologies, notably Viaskin, a revolutionary patch for desensitizing patients. Based in France, DBV Technology is listed on the stock exchange and collaborates with numerous research institutes worldwide.
DBV Technology: key figures for 2023
The year 2023 was marked by significant results for DBV Technology. The company recorded sales growth of 15%, reaching โฌ100 million. This performance was mainly due to increased sales of Viaskin Peanut, which has been approved by several health authorities. In addition, investment in research and development rose by 20%, reflecting DBV's ongoing commitment to innovation.
Financial news and upcoming projects
DBV Technology is not stopping there! The company plans to launch two new products in partnership with Nestlรฉ by 2025: Viaskin Milk and Viaskin Egg, for milk and egg allergies respectively. These promising projects are supported by a recent โฌ50 million fund-raising round, aimed at accelerating their development and commercialization. DBV is also exploring new markets in Asia and South America, with strategic partnerships under negotiation.
Its technological advances, solid financial performance and ambitious projects make it a key player in the biotech sector. Stay tuned so you don't miss any of their next steps!
